Abiopharma

General Announcement: Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2026

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.

X-energy, SGL Carbon Announce Capacity Expansion for Nuclear-Grade Graphite

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health

Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome

Second Quarter 2026 Resultsate Report

Seaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress

EVA LIVE INC. ANNOUNCES FORMATION OF EVA DEFENSE ADVISORY BOARD, APPOINTS GENERAL ROBERT BROOKS BROWN (R) AND ROSS MANDEL

Tonix Pharmaceuticals Announces Positive Minutes from Type C FDA Meeting to Discuss Adaptive Phase 2 Field Study of TNX-4800, a Human, anti-OspA Monoclonal Antibody, to Prevent Lyme Disease in the U.S.